These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9005317)

  • 21. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
    Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
    J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    Witjes WP; Rosier FW; de Wildt MJ; van Iersel MP; Debruyne FM; de La Rosette JJ
    J Urol; 1996 Apr; 155(4):1317-23. PubMed ID: 8632523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study provides head-to-head comparison of terazosin, finasteride.
    Am J Health Syst Pharm; 1996 Oct; 53(20):2380, 2382. PubMed ID: 8899123
    [No Abstract]   [Full Text] [Related]  

  • 24. [Terazosin].
    Schäfers RF; Michel MC
    Dtsch Med Wochenschr; 1998 Apr; 123(15):459-60. PubMed ID: 9581161
    [No Abstract]   [Full Text] [Related]  

  • 25. FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
    Rich KT; Safranek S
    Am Fam Physician; 2008 Mar; 77(5):665-6. PubMed ID: 18350766
    [No Abstract]   [Full Text] [Related]  

  • 26. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
    J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prostatic adenoma: new drugs, new surgical techniques].
    Heinzl S
    Med Monatsschr Pharm; 1992 Dec; 15(12):362-4. PubMed ID: 1282201
    [No Abstract]   [Full Text] [Related]  

  • 30. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
    Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
    Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of alpha 1-blockade in benign prostatic hyperplasia.
    Brawer MK
    J Clin Pharmacol; 1993 Sep; 33(9):891-5. PubMed ID: 7693769
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination drug therapy for benign prostatic hyperplasia.
    Kreder KJ
    JAMA; 1995 Jul; 274(4):359. PubMed ID: 7541871
    [No Abstract]   [Full Text] [Related]  

  • 33. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
    Brawer MK; Adams G; Epstein H
    Arch Fam Med; 1993 Sep; 2(9):929-35. PubMed ID: 7509243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Terazosine in the treatment of benign prostatic hypertrophy].
    Caine M
    J Urol (Paris); 1993; 99(6):311-3. PubMed ID: 7516376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity.
    Liu HP; Chen GL; Liu P; Xu XP
    BJU Int; 2009 Dec; 104(11):1752-7. PubMed ID: 19493262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
    Wien Klin Wochenschr; 1995; 107(15):472-6. PubMed ID: 7545857
    [No Abstract]   [Full Text] [Related]  

  • 37. Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
    Jansen DJ; Resch ND; Hoffman RM
    Am J Health Syst Pharm; 1999 Jul; 56(13):1351. PubMed ID: 10683137
    [No Abstract]   [Full Text] [Related]  

  • 38. [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
    Yang C; Li YL; Fang J; Zhang X; Liu HP; Qin XH; Xu XP
    Zhonghua Nan Ke Xue; 2009 May; 15(5):441-4. PubMed ID: 19514558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Terazosin in the treatment of benign prostatic hypertrophy].
    Andres M; De Cobelli O; Carmignani L; Musci R; Kocjancic E; Panizzutti M; Rocco F
    Arch Ital Urol Androl; 1995 Feb; 67(1):37-9. PubMed ID: 7538386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Sunshine H
    J Urol; 1990 Dec; 144(6):1393-7; discussion 1397-8. PubMed ID: 1700152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.